MSD targets Mankind’s diabetes generic in patent suit
05-04-2022
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
08-02-2022
MPP signs first COVID-19 licensing deal over MSD’s molnupiravir
28-10-2021
Atmosphere1 / Shutterstock.com
Merck Sharp & Dohme (MSD) and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro (ertugliflozin)—a diabetes treatment that Pfizer licences to MSD.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MSD, Pfizer, Hetero Labs, Zenara Pharma, Aurobindo Pharma, US, US District Court for the District of Delaware
